The evolving biosimilar regulations in the United States are poised to create new growth opportunities for Indian pharmaceutical companies, with experts predicting a significant uptick in exports and partnerships in the biopharma segment. The U.S. Food and Drug Administration’s (FDA) streamlined approval pathway for biosimilars, along